By combining proprietary adenoviral technology with complex cellular assays, Charles River’s target discovery group has delivered novel, validated drug targets in a range of therapeutic areas for over 10 years.

We examine the effects of introducing shRNAs (SilenceSelect®) or full-length cDNAs (FLeXSelect®) contained within our libraries of adenoviruses into human primary cells, differentiated stem cells or cell lines. siRNA and miRNA technologies are also available for gene knockdown studies.

Webinar Replay

Vertical Integration of CRISPR/Cas9 Genome Engineering in Drug Discovery

Watch Replay »

I need to...